US Head and Neck Cancer Therapeutics Market Report 2023 to 2030

US Head and Neck Cancer Therapeutics Market Analysis

$ 3999

The US Head and Neck Cancer Therapeutics Market was valued at $512.40 Mn in 2023 and is predicted to grow at a CAGR of 10.50% from 2023 to 2030, to $1030.73 Mn by 2030. The key drivers of this industry include the rising prevalence of Head and Neck cancer, improvement in diagnostic techniques, and growing awareness. The industry is primarily dominated by players such as Eli Lilly and Company, Merck, Bristol Myers Squibb, and AstraZeneca among others.

ID: IN10USPH577 CATEGORY: Pharmaceuticals GEOGRAPHY: US AUTHOR: Aashwi Mehta

Buy Now

US Head and Neck Cancer Therapeutics Market Executive Summary

The US Therapeutics Market was valued at $512.40 Mn in 2023 and is predicted to grow at a CAGR of 10.50% from 2023 to 2030, to $1030.73 Mn by 2030.

Head and neck cancer sites include the squamous cells lining the mucosal surfaces of the head and neck—such as those within the mouth, throat, and larynx (voice box). Head and neck cancers can also start in the salivary glands, sinuses, muscles, or nerves in these areas. Common risk factors include tobacco use, alcohol use, infection with Human Papilloma Virus (HPV), etc. The symptoms of head and neck cancer might include a painful lump in the neck, an ulcer in the mouth or throat that does not go away, trouble swallowing, and a change in voice that sounds hoarse.

The National Cancer Institute (NCI) estimates that in 2024, there will be around 71,100 new cases of head and neck cancer in the US, including cases involving the larynx, pharynx, and oral cavity. Of those cases, 16,110 people are predicted to die from cancer. Approximately 434,915 Americans are currently suffering from pharyngeal and oral cancer, which affects men almost twice as often as women. This data highlights the significant impact of Head and Neck cancer on both men and women in the US. The market is driven by significant factors like the rising prevalence of Head and Neck cancer, improvement in diagnostic techniques, and growing awareness. However, healthcare access disparities, higher costs, and side effects related to treatment restrict the growth and potential of the market.

Prominent players in this field include Eli Lilly and Company, Merck, Bristol Myers Squibb, and AstraZeneca among others.

Market Dynamics

Market Growth Drivers

Rising prevalence of Head and Neck cancer: The National Cancer Institute (NCI) estimates that in 2024, there will be around 71,100 new cases of head and neck cancer in the US, including cases involving the larynx, pharynx, and oral cavity. Of those cases, 16,110 people are predicted to die from the cancer. Approximately 434,915 Americans are currently suffering from pharyngeal and oral cancer, which affects men almost twice as often as women. The head and neck cancer therapeutics market in the US is rising despite a 69 percent five-year survival rate for patients with oral cavity or pharynx cancer. These high incidence and prevalence rates highlight the growing need for efficient treatments.

Improvement in diagnostic technique: The advancement of early detection and monitoring brought about by innovation in diagnostic technology such as a non-invasive urine-based test that can identify tumor DNA fragments in place of conventional blood-based biomarker testing for head and neck cancer, could result in better patient outcomes. The demand for efficient head and neck cancer treatments will likely rise as a result, leading to an expansion of the therapeutic market in the US.

Growing awareness: Head and Neck Cancer Awareness Month is an initiative to increase public awareness of head and neck cancers, led by the Head and Neck Cancer Alliance with assistance from the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS). Every April, the program offers free cancer screenings, educational lectures, and other awareness-raising activities to highlight the significance of early diagnosis for effective treatment. The market for head and neck cancer therapies in the US is developing as a result of increased demand for efficient treatments brought on by the increased rates of early detection and diagnosis.

Market Restraints

Healthcare Access Disparities: In 2023, the federal Agency for Healthcare Research and Quality (AHRQ) found that on 52% of quality metrics, Black patients received worse care than White patients. Significant differences in patient safety and care quality across a range of illnesses, including cancer, were brought to light by the study. Since unequal access to high-quality care might limit treatment efficacy and outcomes for minority populations, these disparities present a market constraint for the head and neck cancer therapeutics market in the US. This will ultimately affect market growth and demand for medicines.

High Treatment Cost: Head and neck cancer treatments in the US are expensive, with prices for early-stage cases starting at $38,000 and going up to $110,000, and for advanced-stage cases, reaching $75,000 to $200,000. These high costs place financial pressure on patients and healthcare systems, which may restrict access to essential treatments and restrict the expansion of the market for head and neck cancer treatments.

Side Effects of Treatment: Treatments for head and neck cancer, such as radiation and chemotherapy, can have serious side effects, such as mucositis, dysphagia, and xerostomia. Patients' quality of life is greatly impacted by these side effects, which may cause them to stop taking their medication or not comply with it. Because it makes treatment adherence and effectiveness more difficult, the high frequency of severe side effects serves as a market restraint, which in turn lowers overall demand for these medicines.

Regulatory Landscape and Reimbursement Scenario

To ensure the safety and effectiveness of pharmaceutical products, the US Food and Drug Administration (US FDA) regulates their production, imports, distribution, and marketing within the country. Strict guidelines are upheld by this regulatory structure to safeguard public health and regulate the pharmaceutical industry. Medicaid, a state-based health insurance program, can cover eligible low-income cancer patients' treatments, giving crucial financial support for head and neck cancer treatments. For many patients, access to essential cancer therapies is guaranteed by Medicare, a federal program that provides coverage for individuals 65 years of age or older or those with certain disabilities.

Competitive Landscape

Key Players

Here are some of the major key players in the US Head and Neck Cancer Therapeutic Market

Eli Lilly and Company
Merck
Bristol Myers Squibb
AstraZeneca
Pfizer
Novartis
Sanofi
Amgen
Roche
Teva Pharmaceuticals

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

US Head and Neck Cancer Therapeutics Market Segmentation

By Treatment

Targeted Therapy
Immunotherapy
Radiation Therapy
Surgeries

By End Users

Hospitals
Specialty Centers
Ambulatory Surgical Centers

By Distribution Channel

Hospital-based pharmacies
Retail pharmacies
Online pharmacies

By Route of administration

Injectable
Oral

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.